Ignite Creation Date:
2024-05-06 @ 9:50 AM
Last Modification Date:
2024-10-26 @ 12:20 PM
Study NCT ID:
NCT03093922
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-12-28
First Post:
2017-03-23
Brief Title:
A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Organization Data
Organization:
Memorial Sloan Kettering Cancer Center
Class:
OTHER
Study ID:
16-1621
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Ohio State University | OTHER |
| University of Chicago | OTHER |
| Genentech Inc | INDUSTRY |
| Targos | UNKNOWN |